{"id":"W3168647721","doi":"10.1200/jco.2021.39.15_suppl.9504","title":"Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Clinical endpoint; Oncology; Tolerability; Adjuvant; Phases of clinical research; Lenvatinib; Clinical trial; Adverse effect; Melanoma; Immunotherapy; Cancer; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002657989,0.0004264548,0.0009960628,0.0005058417,0.0001193019,0.0007739603,0.0006290025,0.0002762977,0.001697763],"category_scores_gemma":[0.0023786,0.0002644866,0.001452342,0.0008882745,0.0001387251,0.0005886455,0.0004526646,0.0007462025,0.0002759668],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008913517,"about_ca_system_score_gemma":0.0008767683,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00154599,"about_ca_topic_score_gemma":0.005680612,"domain_scores_codex":[0.9992169,0.0003655399,0.00008897547,0.00010464,0.000160299,0.00006354449],"domain_scores_gemma":[0.9989396,0.0002953165,0.0005087485,0.00006894196,0.0000965871,0.00009084367],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1402663,0.001578592,0.126495,0.006050624,0.01261072,0.0005647464,0.0002783213,0.004529572,0.01494902,0.0003530912,0.01657953,0.6757445],"study_design_scores_gemma":[0.06765938,0.07116714,0.7281551,0.0016172,0.02880742,0.003482396,0.0003053992,0.005130506,0.006861344,0.0009244421,0.08573977,0.0001498612],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9119942,0.05764933,0.001869916,0.001468417,0.0001630387,0.001960032,0.01502461,0.0002249518,0.009645565],"genre_scores_gemma":[0.9690388,0.01205047,0.002755075,0.001332553,0.0001881641,0.0006636824,0.01226118,0.00004588918,0.001664188],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002657989,"threshold_uncertainty_score":0.01405698,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06523484828108818,"score_gpt":0.4335973311264207,"score_spread":0.3683624828453326,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}